NASDAQ:ARTL Artelo Biosciences Q2 2026 Earnings Report $0.77 +0.02 (+2.49%) As of 01:40 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Artelo Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.72Beat/MissN/AOne Year Ago EPSN/AArtelo Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArtelo Biosciences Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Artelo Biosciences Earnings HeadlinesArtelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with NaproxenJuly 16, 2026 | quiverquant.comQArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain ConditionsJuly 16, 2026 | globenewswire.comWhite House Insider: “President Trump is Getting Backstabbed!”A high-level White House insider and lifelong friend of the Trump family recently went on camera with a warning he's calling 'the biggest political betrayal in America's history.' According to Paradigm Press VP of Research Aaron Gentzler, what was revealed could have a major impact on your wealth in the coming months and years.August 6 at 1:00 AM | Paradigm Press (Ad)Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026July 14, 2026 | globenewswire.comArtelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer PatientsJuly 13, 2026 | quiverquant.comQArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral NeuropathyJuly 13, 2026 | globenewswire.comSee More Artelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email. Email Address About Artelo BiosciencesArtelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes. The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia. In parallel, Artelo is advancing AB188, a topical formulation aimed at treating ocular surface diseases such as dry eye syndrome. Earlier-stage preclinical candidates are being explored for inflammatory and cardiometabolic indications, reflecting the versatility of Artelo’s platform technology in shaping molecular properties to target diverse disease pathways. Founded as a Delaware corporation, Artelo Biosciences is headquartered in Cleveland, Ohio, and conducts research and development activities in the United States. The executive leadership team brings together expertise in medicinal chemistry, pharmaceutical development and regulatory strategy. Artelo continues to engage with key opinion leaders and strategic partners to support its pipeline through proof-of-concept studies and toward eventual regulatory filings.View Artelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Bed Bath & Beyond Renovates: The Neighborhood BlueprintSpaceX: Love the Company, But the Stock Is a Harder CallDisney Sets Up for a Magical Year in 2027Astera Labs' Post-Earnings Pullback May Be Last Chance to Buy Below $360Why Analysts Are Bullish on a Stock That's Down 20%Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next? Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
